Topical bacterial lysates in the treatment of patients with infectious and inflammatory diseases of the ENT organs

Infectious and inflammatory diseases of the upper respiratory tract occupy one of the leading positions in the overall morbidity structure of the population worldwide. Among these diseases, the pharynx, nasal cavity and paranasal sinuses are most often affected. Against this background, the resistance of certain pathogens to etiotropic drugs is growing and the arsenal of pathogenetic therapies is insufficient, which creates the need to find alternative medicines. One of the possible alternative therapy options is a group of immunomodulatory drugs, among which bacterial lysates are the most popular. There is already sufficient evidence in the modern literature on the efficacy and safety of bacterial lysate preparations. Topical bacterial lysates have a stimulating effect on various links of specific and nonspecific immunity. They act directly in the focus of the disease, do not harm the body’s own microbiome, combine well with other medicines and can be used in patients of any age. Bacterial lysates are considered as an effective component of therapy of infectious and inflammatory diseases of the upper respiratory tract. They lead to the elimination of pathogenic pathogens, stimulate the body’s own defense mechanisms, and also contribute to the restoration of autoregulation of the local immune response. The use of bacterial lysate preparations leads to the activation of mucosal immunity and a decrease in the incidence of infectious diseases. Topical immunomodulators also have a preventive effect, preventing the occurrence of possible respiratory infections and improving the quality of life of patients. The use of drugs bacterial lysates show good clinical results, they contribute to improving the effectiveness of therapy and preventive measures.

1. Eremin SA, Dvorianchikov VV, Ryazantsev SV, Pavlova SS, Sitnikov SI. Patterns of pathogenetic antibacterial therapy concerning ENT organs in modern conditions. RMJ. 2023;(1):32–37. (In Russ.) Available at: https://www.rmj.ru/articles/otorinolaringologiya/Osobennosti_patogeneticheskoy_antibakterialynoy_terapii_LOR-organov_v_sovremennyh_usloviyah.

2. Svistushkin VM, Starostina SV, Avetisyan EE, Selezneva LV. Possibilities of immunostimulating therapy in respiratory infections of upper respiratory tracts. Meditsinskiy Sovet. 2017;(8):8–12. (In Russ.) https://doi.org/10.21518/2079-701X-2017-8-8-12.

3. Kasatkin AN, Fomina AV. Analysis of the prevalence of diseases of ENT organs and their medical and social significance. Current Problems of Health Care and Medical Statistics. 2024;(2):338–351. (In Russ.) https://doi.org/10.24412/2312-2935-2024-2-338-351.

4. Shakhov AV, Krasilnikova SV. Efficacy of topical bacterial lysates in inflammatory diseases of the oral cavity and pharynx. Meditsinskiy Sovet. 2023;17(7):20–25. (In Russ.) https://doi.org/10.21518/ms2023-114.

5. Starostina SV, Svistushkin VM. Wide possibilities of topical therapy in the treatment of patients with infectious and inflammatory diseases of the pharynx. Meditsinskiy Sovet. 2024;18(18):24–30. (In Russ.) https://doi.org/10.21518/ms2024-469.

6. Kumpitsch C, Koskinen K, Schöpf V, Moissl-Eichinger C. The microbiome of the upper respiratory tract in health and disease. BMC Biol. 2019;17(1):87. https://doi.org/10.1186/s12915-019-0703-z.

7. Borisova OV, Bochkareva NM, Polezhaeva NS, Yashkina ON, Tsareva NG, Gadelshina DM. Antibiotic therapy in pediatric outpatient ENT infections. Meditsinskiy Sovet. 2024;18(1):46–52. (In Russ.) https://doi.org/10.21518/ms2024-029.

8. Karpischenko SA, Kolesnikova OM. Topical therapy of acute tonsillopharyngitis. RMJ. 2022;(2):50–54. (In Russ.) Available at: https://www.rmj.ru/articles/otorinolaringologiya/Mestnaya_terapiya_ostrogo_tonzillofaringita.

9. Korchagina SA. Analysis of the spectrum of microflora and antibiotic resistance of the main pathogens in the pathology of ENT organs. Molodezhnyy Innovatsionnyy Vestnik. 2022;9(S2):121–124. (In Russ.) Available at: https://elibrary.ru/bviqya.

10. Ryazantsev SV, Krivopalov AA, Eremin SA. Features of nonspecific prevention and treatment of patients with exacerbation of chronic tonsillitis. RMJ. 2017;(23):1688–1694. (In Russ.) Available at: https://www.rmj.ru/articles/otorinolaringologiya/Osobennosti_nespecificheskoy_profilaktiki_i_lecheniya_pacientov_s_obostreniem_hronicheskogo_tonzillita.

11. Rahman MM, Grice ID, Ulett GC, Wei MQ. Advances in Bacterial Lysate Immunotherapy for Infectious Diseases and Cancer. J Immunol Res. 2024;2024:4312908. https://doi.org/10.1155/2024/4312908.

12. Luss LV. Secondary immunodeficiency in children. The clinician’s view immunomodulators prescription. Allergology and Immunology in Pediatrics. 2018;55(4):4–18. (In Russ.) https://doi.org/10.24411/2500-1175-2018-00017.

13. Svistushkin VM, Nikiforova GN, Zolotova AV, Stepanova VA. Using of topical bacterial lysates in modern clinical practice. Meditsinskiy Sovet. 2021;(6):49–56. (In Russ.) https://doi.org/10.21518/2079-701X-2021-6-49-56.

14. Gioacchino MD, Santilli F, Pession A. Is There a Role for Immunostimulant Bacterial Lysates in the Management of Respiratory Tract Infection? Biomolecules. 2024;14(10):1249. https://doi.org/10.3390/biom14101249.

15. Markova TP, Yarilina LG, Chuvirova AG. Bacterial lysates. New drugs. RMJ. 2014;(24):1764–1767. (In Russ.) Available at: https://www.rmj.ru/articles/klinicheskaya_farmakologiya/Bakterialynye_lizaty_Novye_preparaty.

16. Suárez N, Ferrara F, Rial A, Dee V, Chabalgoity JA. Bacterial Lysates as Immunotherapies for Respiratory Infections: Methods of Preparation. Front Bioeng Biotechnol. 2020;8:545. https://doi.org/10.3389/fbioe.2020.00545.

17. Cazzola M, Anapurapu S, Page CP. Polyvalent mechanical bacterial lysate for the prevention of recurrent respiratory infections: a meta-analysis. Pulm Pharmacol Ther. 2012;25(1):62–68. https://doi.org/10.1016/j.pupt.2011.11.002.

18. Jurkiewicz D, Zielnik-Jurkiewicz B. Bacterial lysates in the prevention of respiratory tract infections. Otolaryngol Pol. 2018;72(5):1–8. https://doi.org/10.5604/01.3001.0012.7216.

19. Zaplatnikov AL, Kanner EV, Kanner ID, Girina AA, Farber IM, Maksimov ML. Promising immunomodulatory effects of bacterial lysates in the prevention and treatment of acute and recurrent respiratory infections in children. Russian Journal of Woman and Child Health. 2023;(3):290–297. (In Russ.) https://doi.org/10.32364/2618-8430-2023-6-3-12.

20. Ferrara F, Rial A, Suárez N, Chabalgoity JA. Polyvalent Bacterial Lysate Protects Against Pneumonia Independently of Neutrophils, IL-17A or Caspase-1 Activation. Front Immunol. 2021;12:562244. https://doi.org/10.3389/fimmu.2021.562244.

21. Bartkowiak-Emeryk M, Emeryk A, Roliński J, Wawryk-Gawda E, Markut-Miotła E. Impact of Polyvalent Mechanical Bacterial Lysate on lymphocyte number and activity in asthmatic children: a randomized controlled trial. Allergy Asthma Clin Immunol. 2021;17(1):10. https://doi.org/10.1186/s13223-020-00503-4.

22. Lee YK, Haam JH, Suh E, Cho SH, Kim YS. A Case-Control Study on the Changes in Natural Killer Cell Activity following Administration of Polyvalent Mechanical Bacterial Lysate in Korean Adults with Recurrent Respiratory Tract Infection. J Clin Med. 2022;11(11):3014. https://doi.org/doi:10.3390/jcm11113014.

23. Bosco A. Emerging role for interferons in respiratory viral infections and childhood asthma. Front Immunol. 2023;14:1109001. https://doi.org/doi:10.3389/fimmu.2023.1109001.

24. Dang AT, Pasquali C, Ludigs K, Guarda G. OM-85 is an immunomodulator of interferon-β production and inflammasome activity. Sci Rep. 2017;7:43844. https://doi.org/doi:10.1038/srep43844.

25. Rial A, Ferrara F, Suárez N, Scavone P, Marqués JM, Chabalgoity JA. Intranasal administration of a polyvalent bacterial lysate induces self-restricted inflammation in the lungs and a Th1/Th17 memory signature. Microbes Infect. 2016;18(12):747–757. https://doi.org/doi:10.1016/j.micinf.2016.10.006.

26. Kearney SC, Dziekiewicz M, Feleszko W. Immunoregulatory and immunostimulatory responses of bacterial lysates in respiratory infections and asthma. Ann Allergy Asthma Immunol. 2015;114(5):364–369. https://doi.org/doi:10.1016/j.anai.2015.02.008.

27. Radtsig EYu, Radtsig AN, Varavina MA. Protective properties of the mucosa of the upper respiratory tract and methods of their activation. Russian Bulletin of Perinatology and Pediatrics. 2021;66(1):140–146. (In Russ.) https://doi.org/10.21508/1027-4065-2021-66-1-140-146.

28. Sidoti Migliore G, Pezzino G, Cavaliere R, De Pasquale C, Ferlazzo G. On immunostimulants and dendritic cell activation. Immunol Lett. 2021;232:45–47. https://doi.org/10.1016/j.imlet.2021.02.004.

29. Macri C, Fancke B, Radford KJ, O’Keeffe M. Monitoring Dendritic Cell Activation and Maturation. Methods Mol Biol. 2019;1988:403–418. https://doi.org/10.1007/978-1-4939-9450-2_28.

30. Gaudino SJ, Kumar P. Cross-Talk Between Antigen Presenting Cells and T Cells Impacts Intestinal Homeostasis, Bacterial Infections, and Tumorigenesis. Front Immunol. 2019;10:360. https://doi.org/10.3389/fimmu.2019.00360.

31. Aarestrup PF, Aarestrup MF, Aarestrup BJV, Aarestrup FM. Prophylaxis of Upper Airway Infections in a Patient with Partial IgA Deficiency: Concurrent Use of Sublingual Immunotherapy with Inactivated Whole-Cell Bacterial Extract and Der p1. Case Rep Otolaryngol. 2020;2020:6313176. https://doi.org/10.1155/2020/6313176.

32. Ballarini S, Ardusso L, Ortega Martell JA, Sacco O, Feleszko W, Rossi GA. Can bacterial lysates be useful in prevention of viral respiratory infections in childhood? The results of experimental OM-85 studies. Front Pediatr. 2022;10:1051079. https://doi.org/10.3389/fped.2022.1051079.

33. Pasquali C, Salami O, Taneja M, Gollwitzer ES, Trompette A, Pattaroni C et al. Enhanced Mucosal Antibody Production and Protection against Respiratory Infections Following an Orally Administered Bacterial Extract. Front Med (Lausanne). 2014;1:41. https://doi.org/10.3389/fmed.2014.00041.

34. Lanzilli G, Traggiai E, Braido F, Garelli V, Folli C, Chiappori A et al. Administration of a polyvalent mechanical bacterial lysate to elderly patients with COPD: Effects on circulating T, B and NK cells. Immunol Lett. 2013;149(1-2):62–67. https://doi.org/10.1016/j.imlet.2012.11.009.

35. Zaplatnikov AL, Girina AA, Burtseva EI, Lepiseva IV, Maikova ID, Svintsitskaya VI et al. Acute, recurrent and recurrent respiratory tract infections in children: issues of immunoprophylaxis and immunotherapy. Russian Journal of Woman and Child Health. 2023;6(1):50–59. (In Russ.) https://doi.org/10.32364/2618-8430-2023-6-1-50-59.

36. Kryshen KL, Gaidai DS, Gushchin YA, Makarova МN, Makarov VG, Kalyuzhin OV. Bacterial Lysate Complex Administered Intranasally Suppresses Inflammation in an In Vivo Model of Aseptic Lymphadenitis. Bull Exp Biol Med. 2022;173(3):361–365. https://doi.org/10.1007/s10517-022-05549-5.

37. Zaplatnikov AL, Girina AA, Lepiseva IV, Svintsitskaya VI. Topical bacterial lysates in pediatric practice. Farmateka. 2020;27(9):31–37. (In Russ.) https://doi.org/10.18565/pharmateca.2020.9.31-37.

38. Ivanova ON, Ivanova IS. Treatment of Recurrent Stomatitis in Children. Challenges in Modern Medicine. 2023;46(4):384–391. (In Russ.) https://doi.org/10.52575/2687-0940-2023-46-4-384-391.

39. Новрузова МСК, Талыбова ДХК, Шихалиев ФМО, Байрамова РСК, Гасымова МЧК. Применение Имудона при лечении тонзиллофарингитов. В: Просветительская деятельность как форма коммуникации в науке и образовании. Казань: САНТРЕМ; 2022. 91 с. Режим доступа: https://elibrary.ru/priyej.

40. Kryshen KL, Kukharenko AE, Vichare AS, Gaidai EA, Kryshen AA, Gushchin YaA et al. Anti-inflammatory and immunomodulating effects of the bacterial lysate in the in vivo models of aseptic lymphadenitis and pneumococcal pneumonia. Medical Immunology (Russia). 2020;22(1):111–122. (In Russ.) https://doi.org/10.15789/1563-0625-AAI-1758.

41. Zaplatnikov AL, Girina AA, Svintsitskaya VI, Lepiseva IV, Leshik MV. Bacterial lysates: traditional concepts and a new paradigm. Russian Journal of Woman and Child Health. 2021;4(3):284–291. (In Russ.) https://doi.org/10.32364/2618-8430-2021-4-3-284-291.

42. Vladimirova TA, Martynova AS. The effectiveness of the use of topical bacterial lysates in frequently ill children with pharyngeal tonsil hypertrophy and/or exacerbation of chronic adenoiditis. Meditsinskiy sovet . 2023;(19):88–95. (In Russ.) https://doi.org/10.21518/ms2023-371.

43. Drozdova MV, Preobrazhenskaya YuS, Ryazantsev SV, Pavlova SS. Inflammatory diseases of the pharynx in children. Meditsinskiy Sovet. 2022;(1):51–57. (In Russ.) https://doi.org/10.21518/2079-701X-2022-16-1-51-57.

44. Luchikhin LA. The use of imunocorrection therapy for the combined treatment of the inflammatory diseases of the pharynx. Vestnik Oto-Rino-Laringologii. 2012;77(5):48–51. (In Russ.) Available at: https://www.mediasphera.ru/issues/vestnik-otorinolaringologii/2012/5/030042-46682012511.

45. Dubinets ID, Korkmazov AM, Angelovich MS, Solodovnik AV, Mirzagaliev DM. Prospects for the use of bacterial lysates in the complex therapy of chronic adenoiditis. Meditsinskiy Sovet. 2021;(18):69–79. (In Russ.) https://doi.org/10.21518/2079-701X-2021-18-69-79.

46. Zakirova AM, Krasnozhen VN, Shayapova DT, Kadriev AG, Rashitova EL, lbragimov TM, Kadriev AA. Еffectiveness of immunocorrective therapy for frequently ill children. Meditsinskiy Sovet. 2024;(7):98–109. (In Russ.) https://doi.org/10.21518/ms2024-067.

47. Garashchenko TI, Alferova MV, Zelenkova IV. Immunomodulators of topical application in the prevention and treatment of chronic adenoiditis in children. Vestnik Oto-Rino-Laringologii. 2011;(2):62–65. (In Russ.) Available at: https://www.mediasphera.ru/issues/vestnik-otorinolaringologii/2011/2.